NCT00746941 - Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions

Progressive Multifocal Leukoencephalopathy

Interventions

DRUG

mefloquine

250 mg orally each day for 3 days and then weekly up to 6 months.

Trial Locations (12)

Research Site, Chicago

Research Site, Baltimore

Research Site, Boston

Research Site, St Louis

Research Site, New York

Research Site, São Paulo

Research Site, Düsseldorf

Research Site, Berlin

Research Site, Hamburg

Research Site, Milan

Research Site, Barcelona

Research Site, Madrid